

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/185921 A1

(43) International Publication Date
23 September 2021 (23.09.2021)

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 38/19* (2006.01)
A61K 9/08 (2006.01) *A61P 11/00* (2006.01)
A61K 47/10 (2017.01) *A61P 31/04* (2006.01)
A61K 47/26 (2006.01) *A61P 11/04* (2006.01)
A61K 47/42 (2017.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2021/056851

(22) International Filing Date:

17 March 2021 (17.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/990,810 17 March 2020 (17.03.2020) US
20164648.6 20 March 2020 (20.03.2020) EP

(71) Applicant: **DRUGRECURE APS** [DK/DK]; Slotsmarken 17, 2. tv., 2970 Hørsholm (DK).

(72) Inventors: **SKRIVER, Lars**; Slotsmarken 17, 1th., 2970 Hørsholm (DK). **WATTS, Alan**; Slotsmarken 17, 1th., 2970 Hørsholm (DK).

(74) Agent: **HØIBERG P/S**; Adelgade 12, 1304 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv))

(54) Title: LIQUID FORMULATION OF GM-CSF FOR INHALATION

(57) Abstract: Provided here is a liquid formulation comprising recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) for inhalation by nebulization.

WO 2021/185921 A1